Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating for Dyne Therapeutics, maintaining a price target of $55.
September 03, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating for Dyne Therapeutics, maintaining a price target of $55.
The reiteration of an Outperform rating and a maintained price target of $55 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100